Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Product Launch

18 Nov 2005 07:00

Original Investments PLC18 November 2005 Original Investments PLC ("Original Investments" or "the Company") Commercial product launch from Acrobot Visualisation software, enabling orthopaedic surgeons to producethree-dimensional bone surface models from Computed Tomography (CT) scans forpre-operative surgical planning, is launched today by The Acrobot Company("Acrobot"). Acrobot is a spin-out company from Imperial Innovations, the technologycommercialization company of Imperial College, London, and develops surgicalsystems for minimally-invasive, bone-conserving orthopaedic surgery. TheAIM-quoted company Original Investments (formerly BioProjects International)owns 25% of Acrobot's equity. The new software, called the Acrobot(R) Planner, is Acrobot's first commercialproduct and is being provided free of charge to surgeons who register to use it.Acrobot will receive fees for data preparation and bone modeling. The Acrobot(R) Planner gives the user the ability to visualise a patient's threedimensional bone surface models built from CT scans. The visualisation isinteractive and the user can select and position implant models onto the bones,evaluate the resulting range of motion, and produce reports. "The software will enable surgeons to assess accurately the exact requirementfor each operation and precisely plan the procedure beforehand," says Dr. PaulaGomes, Acrobot's Director of Operations. "It will help to reduce surgicalerrors, surgeon's stress, and overall procedure costs and times. Radiologistswill also use the software to produce enhanced reports." Further uses for the software will be as a powerful tool for teaching and alsogenerating visual material for presentations. Acrobot provides a commercial service for Acrobot(R) Planner users by taking theraw CT DICOM data, segmenting them and building bone surface models from theinformation. The user can import these patient-specific models into thesoftware, and perform hip resurfacing pre-operative surgical planning and/ orimpingement analysis. The data processing service removes the need for the userto be involved in time-consuming routine data preparation tasks. The Acrobot(R) Planner has been developed by the Acrobot team at the company'slaboratories in London's Leathermarket. It is the first of a number of relatedproducts to be produced by Acrobot, which was founded six years ago by ImperialInnovations as a collaboration to combine the skills of clinicians andacademics. Acrobot is initially focusing on developing precision surgical systems forminimally-invasive techniques in knee and hip replacement. With each product theoverall aims are to reduce error, increase accuracy and enable more difficultsculpted surfaces to be achieved for the new generation of 'resurfacing' orpartial joint implants. Products planned for launch in 2006 include the Acrobot(R) Navigation System,which provides visual guidance for the surgeon and is now undergoing regulatoryapproval, and the Acrobot Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. "We are delighted that our faith in Acrobot is beginning to bear commercialfruit," said Terry Bond, managing director of Original Investments. "Four yearsago we were the first investors outside Imperial College to provide seed-cornfunding for the company and we have continued to support it through the variousstages of its development." Further information on Original Investments PLC from Terry Bond, ManagingDirector, 01235 834734. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.